HIV HAART AIDS SIDA VIH HIV
insulin resistance C-Reactive protein (CRP)
  Español (soon!) - October 11, 2008
CMEonHIV.com is dedicated to providing online CME presentations (slides with voiceover) on HIV/AIDS for healthcare professionals given by local and international experts to keep you up-to-date on the ongoing developments in the field.
 Conference
"Maintenance Without Sacrifice - A Way to Optimise HIV Treatment"
Dr. Giuseppe Pantaleo (biography)
English - 2004-05-25 - 42 minutes
(58 slides)

Summary :
In this presentation, Dr. Pantaleo discusses how changes in antiretroviral maintenance therapy can be used to optimize the treatment of HIV.

HIV patients on highly-active anti-retroviral therapy (HAART) may benefit from a simplification in their regimen, says Dr. Pantaleo, with reduced toxicities and side-effects, improved quality of life and patient satisfaction, and, ultimately, improved adherence to treatment. However, a simplified regimen must, nonetheless maintain virologic control.

Dr. Pantaleo examines the results of a number of studies that compare continued protease inhibitor-containing HAART with NRTI triple therapy, as well as with an NNRTI plus NRTI dual therapy. Patient populations include those HIV patients with either low or high pre-HAART viral RNA loads, as well as those who have received either optimal or sub-optimal therapy pre-HAART.


Copyright © 2004 E-MedHosting.com Inc

Learning objectives :
After viewing this presentation, the participant will be able to discuss the safety and efficacy of:

• Switch maintenance therapy with a triple-NRTI or dual NRTI+NNRTI regimen versus continued therapy with a PI-based regimen
• Switch maintenance therapy in patients with sub-optimal therapy prior to HAART
• Maintenance therapy in patients with a high viral load at baseline
• Abacavir (ABC) substitution in patients with dyslipidemia and/or lipoatrophy on a first-line therapy of stavudine (d4T) plus a PI or NNRTI

Bibliographic references :
Clumeck N, Goebel F, Rozenbaum W, Gerstoft J, Staszewski S, Montaner J, Johnson M, Gazzard B, Stone C, Athisegaran R, Moore S; CNA30017 Study Team. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001; 15(12): 1517-26.

Katlama C, Fenske S, Gazzard B, Lazzarin A, Clumeck N, Mallolas J, Lafeuillade A, Mamet JP, Beauvais L; AZL30002 European study team. TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med 2003; 4(2): 79-86.

Maggiolo F, Ripamonti D, Ravasio L, Gregis G, Quinzan G, Callegaro A, Arici C, Suter F. Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infection. Clin Infect Dis. 2003; 37(1): 41-9.

Martinez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, Knobel H, Riera M, Pedrol E, Force L, Llibre JM, Segura F, Richart C, Cortes C, Javaloyas M, Aranda M, Cruceta A, de Lazzari E, Gatell JM; Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349(11): 1036-46.

Moyle GJ, Gazzard BG. Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis. AIDS 2002; 16(7): 1086-7.

Moyle GJ, Baldwin C, Langroudi B, Mandalia S, Gazzard BG. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr 2003; 33(1): 22-8.

Opravil M, Hirschel B, Lazzarin A, Furrer H, Chave JP, Yerly S, Bisset LR, Fischer M, Vernazza P, Bernasconi E, Battegay M, Ledergerber B, Gunthard H, Howe C, Weber R, Perrin L; Swiss HIV Cohort Study. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002; 185(9): 1251-60.

   


  Login

  Please log in and get access to thousands of resources about HIV disease and its treatment.
 
Already a member?
  Username :
  Password :
   
 
  Lost your password?


  Search our database
  Find the information that you are looking for in over +3000 resources.
 
web cmeonhiv.com



ezCME: HIV - Insulin Resistance - C-Reactive Protein (CRP) - ADHD - Sleep Disorder - Prostate Health - Hemophilia - Transplantation

CMEonHIV is owned by E-MedHosting.com.

Copyright @ 2002-2008 E-MedHosting.com. All rights reserved.  Disclaimer  |  Sponsor Disclaimer


USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR
BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.